Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Investigators conducted polygraph interviews as part of the effort to determine what happened to Lilly and Jack Sullivan.

The Houston-based Empower Pharmacy is seeking to dismiss a lawsuit that targets its ability to sell popular diabetes and ...

Eli Lilly ( LLY 0.36%) has been a great growth pick for investors over the past few years. The pharma company, thanks to its ...

Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

If Eli Lilly presents strong data, the stock could be set to rally and potentially be on a path to reaching new highs. Should ...

The deal is Lilly’s second obesity tie-up in a week, after sinking up to $870 million into an agreement with Camurus to ...

Companies are always in the race for the top spot, and the only way to achieve it is by reaching a high market valuation. The ...

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, ...

Shares of Eli Lilly & Co. LLY rallied 4.33% to $807.19 Tuesday, on what proved to be an all-around positive trading session ...